3 withdrawn. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Withdrawn 3 |
Follow Insomnia: new trials by email Literature Review of Insomnia trials Research Report on Insomnia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy of CALPXT96™in Improving Sleep Quality in Patients With Chronic Non-cancer Pain CALPXT96 - Chronic Pain, Insomnia | Phase 3 | Withdrawn | 9305-9954 Quebec Inc | 2015-12-01 | 2017-04-26 | |
| An Exploratory Study of NBI-34060 Capsules and Next Day Functioning NBI-34060 - Insomnia | Phase 3 | Withdrawn | Neurocrine Biosciences | 2007-09-01 | 2015-05-12 | |
| An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007) MK0928, gaboxadol / Duration of Treatment: 10 months - Insomnia | Phase 3 | Withdrawn | H. Lundbeck A/S | 2005-01-01 | 2015-01-14 |
Sleep Initiation and Maintenance Disorders (3) · Chronic Pain (1) · Pain (1)
Dyssomnias (3) · Mental Disorders (3) · Nervous System Diseases (3) · Sleep Disorders, Intrinsic (3) · Sleep Wake Disorders (3) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Duration of Therapy (1) · gaboxadol (1)
9305-9954 Quebec Inc (1) · H. Lundbeck A/S (1) · Neurocrine Biosciences (1)
Canada (1) · United States (1)
Gary K. Zammit, PhD (1) · James Ducharme, MD CM (1)